MEK inhibitors for pre-treated, NRAS-mutated metastatic melanoma: A multi-centre, retrospective study-Reference-Cited by-同舟云学术

MEK inhibitors for pre-treated, NRAS-mutated metastatic melanoma: A multi-centre, retrospective study

Published:2022-05 Issue: Volume:166 Page:24-32
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Salzmann Martin^ORCID,Pawlowski Johannes,Loquai Carmen,Rafei-Shamsabadi David A.^ORCID,Meiss Frank^ORCID,Ugurel Selma,Schadendorf Dirk^ORCID,Meier Friedegund^ORCID,Enk Alexander H.^ORCID,Hassel Jessica C.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference32 articles.

1. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma;Larkin;N Engl J Med,2015

2. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial;Hodi;Lancet Oncol,2018

3. Pembrolizumab versus ipilimumab in advanced melanoma;Robert;N Engl J Med,2015

4. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma;Larkin;N Engl J Med,2014

5. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study;Long;Ann Oncol : Off J Euro Soc Med Oncol,2017

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NRAS melanoma response to trametinib and azacitidine;Pediatric Blood & Cancer;2024-09-09

2. Therapeutic advances of targeting receptor tyrosine kinases in cancer;Signal Transduction and Targeted Therapy;2024-08-14

3. Molecularly matched targeted therapy: a promising approach for refractory metastatic melanoma;The Oncologist;2024-05-18

4. Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy;Journal of Experimental & Clinical Cancer Research;2024-01-23

5. BRAF and MEK inhibitor combinations induce potent molecular and immunological effects in NRAS‐mutant melanoma cells: Insights into mode of action and resistance mechanisms;International Journal of Cancer;2023-12-11